Pharmacolog Appoints New Sales and Marketing Manager
Pharmacolog appoints Kent Öbrink as new Sales and Marketing Manager. Kent has more than 20 years of experience in qualified healthcare sales and a solid international experience. Kent will start on 1 of June and comes from C-Rad AB, where he held the role of Global Sales Manager.
As sales and marketing manager, Kent Öbrink will be responsible for the company’s commercial activities and for collecting important market intelligence before new development projects. Kent is a qualified microbiologist, but soon entered sales and marketing with a job as a Sales Representative at Kabi Pharmacia in 1991. After that, Kent held several qualified sales manager positions within the company until 1999, when he was recruited as sales manager at Fresenius-Kabi. For the past seven years, Kent has worked at C-Rad AB and has been instrumental in developing C-Rad’s sales and marketing organization. During the past four years, he has been acting as Global Sales Manager with responsibility for Europe and the United States.
CEO Mats Högberg comments. “With Kent at the helm of our sales and marketing activities, we are very well equipped to accelerate our commercial activities both internationally and nationally. Kent has a very relevant experience and competence profile for us. With his long experience of working with the sale of innovative technology in small and medium-sized companies in an international market, Kent will be a very valuable addition to our team of experts.”
Aktieägarna i Pharmacolog i Uppsala AB (publ), org.nr 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.
Aktieägare som önskar delta vid årsstämman skall:
– dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och
– dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till firstname.lastname@example.org.
Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...
Continued negotiations with international MedTech Group
In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.
The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...
Extended collaboration with Uppsala University regarding dosage of antibiotics
Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.
The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.
Hans Dahlin, Research Director and Founder, comments: R...
The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.
The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...